Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus SESQUIENT.
DEXFERRUM vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement